orchard
therapeutics
reviews
recent
portfolio
progress
reports
third
quarter
financial
results
libmeldy
tm
receives
positive
chmp
opinion
treatment
metachromatic
leukodystrophy
mld
ind
application
track
year
end
cash
investments
runway
frontotemporal
dementia
ftd
crohn
disease
preclinical
programs
featured
virtual
r
event
november
boston
london
globe
newswire
orchard
therapeutics
nasdaq
ortx
global
gene
therapy
leader
today
reviewed
recent
business
accomplishments
reported
financial
results
quarter
ended
september
positive
chmp
opinion
received
last
month
libmeldy
eu
represents
proud
moment
orchard
offers
potentially
transformative
therapy
mld
patients
families
said
bobby
gaspar
chief
executive
officer
orchard
therapeutics
looking
forward
many
exciting
developments
program
rest
pipeline
coming
months
including
november
investor
event
highlight
work
conditions
larger
patient
populations
ftd
crohn
recent
corporate
achievements
libmeldy
mld
received
positive
chmp
opinion
recommending
full
marketing
authorization
treatment
metachromatic
leukodystrophy
mld
patients
european
union
eu
chmp
positive
opinion
reviewed
european
commission
ec
final
decision
anticipated
end
approved
libmeldy
would
first
commercial
therapy
first
ex
vivo
hematopoietic
stem
cell
hsc
lentiviral
gene
therapy
eligible
patients
mld
link
full
release
received
ema
prime
designation
treatment
link
full
release
presented
additional
interim
data
ongoing
poc
trial
annual
meeting
european
society
blood
bone
marrow
transplantation
ebmt
data
demonstrate
sustained
hematologic
engraftment
eight
patients
treated
preliminary
clinical
data
showing
improved
motor
function
stable
cognitive
scores
continued
normal
growth
first
two
patients
treated
least
one
year
link
full
release
planned
corporate
milestones
libmeldy
mld
obtain
ec
approval
launch
eu
seek
regenerative
medicine
advanced
therapy
rmat
designation
file
investigational
new
drug
ind
application
submit
biologics
license
application
bla
eu
marketing
authorization
application
maa
filings
report
results
initiate
registrational
study
complete
enrollment
poc
study
release
interim
data
research
provide
detail
development
ftd
crohn
disease
programs
november
r
event
third
quarter
financial
results
revenue
product
sales
strimvelis
million
third
quarter
compared
million
period
cost
product
sales
million
third
quarter
compared
million
period
research
development
r
expenses
million
third
quarter
compared
million
period
r
expenses
include
costs
clinical
trials
preclinical
work
company
portfolio
investigational
gene
therapies
well
costs
related
regulatory
manufacturing
license
fees
milestone
payments
company
agreements
third
parties
personnel
costs
support
activities
decline
r
expenses
primarily
attributable
company
research
development
tax
credits
recorded
offset
r
expense
third
quarter
company
recorded
tax
credits
million
compared
million
period
company
realized
savings
associated
updated
strategy
corporate
restructuring
previously
announced
may
including
consolidation
r
sites
selling
general
administrative
expenses
million
third
quarter
compared
million
period
decline
primarily
due
lower
administrative
corporate
expenses
compared
prior
period
primarily
resulting
may
corporate
restructuring
net
loss
million
third
quarter
compared
million
period
lower
net
loss
compared
period
result
higher
research
development
tax
credits
savings
associated
updated
strategic
plan
corporate
restructuring
million
income
primarily
attributable
unrealized
foreign
currency
gains
quarter
company
million
ordinary
shares
outstanding
september
cash
cash
equivalents
investments
september
million
compared
million
december
decrease
primarily
driven
cash
used
fund
operations
nine
months
ended
september
third
quarter
company
received
approximately
million
cash
r
tax
credits
related
result
qualifying
activities
tax
code
company
expects
existing
cash
cash
equivalents
investments
fund
anticipated
operating
capital
expenditure
requirements
excludes
million
expected
available
company
credit
facility
capital
received
potential
future
partnerships
priority
review
vouchers
european
commercial
team
place
executed
activities
necessary
launch
libmeldy
approved
basis
first
half
said
frank
thomas
president
chief
operating
officer
addition
leveraging
cross
border
reimbursement
channels
treatment
patients
parts
world
based
past
experience
webcast
information
november
r
investor
event
company
webcasting
virtual
r
investor
event
starting
et
friday
november
event
accessed
news
events
investors
media
section
company
website
replay
archived
orchard
website
following
event
orchard
orchard
therapeutics
global
gene
therapy
leader
dedicated
transforming
lives
people
affected
rare
diseases
development
innovative
potentially
curative
gene
therapies
ex
vivo
autologous
gene
therapy
approach
harnesses
power
genetically
modified
blood
stem
cells
seeks
correct
underlying
cause
disease
single
administration
orchard
acquired
gsk
rare
disease
gene
therapy
portfolio
originated
pioneering
collaboration
gsk
san
raffaele
telethon
institute
gene
therapy
milan
italy
orchard
one
deepest
advanced
gene
therapy
product
candidate
pipelines
industry
spanning
multiple
therapeutic
areas
disease
burden
children
families
caregivers
immense
current
treatment
options
limited
exist
orchard
global
headquarters
london
headquarters
boston
information
please
visit
follow
us
twitter
linkedin
availability
information
orchard
investors
others
note
orchard
communicates
investors
public
using
company
website
investor
relations
website
social
media
twitter
linkedin
including
limited
investor
presentations
investor
fact
sheets
securities
exchange
commission
filings
press
releases
public
conference
calls
webcasts
information
orchard
posts
channels
websites
could
deemed
material
information
result
orchard
encourages
investors
media
others
interested
orchard
review
information
posted
channels
including
investor
relations
website
regular
basis
list
channels
may
updated
time
time
orchard
investor
relations
website
may
include
additional
social
media
channels
contents
orchard
website
channels
website
may
accessed
website
channels
shall
deemed
incorporated
reference
filing
securities
act
statements
press
release
contains
certain
statements
orchard
strategy
future
plans
prospects
made
pursuant
safe
harbor
provisions
private
securities
litigation
reform
act
statements
may
identified
words
anticipates
believes
expects
plans
intends
projects
future
similar
expressions
intended
identify
statements
statements
include
express
implied
statements
relating
among
things
orchard
business
strategy
goals
including
plans
expectations
regulatory
approval
commercialization
libmeldy
therapeutic
potential
orchard
product
candidates
including
libmeldy
product
candidates
referred
release
orchard
expectations
regarding
timing
regulatory
submissions
approval
product
candidates
including
product
candidates
referred
release
timing
interactions
regulators
regulatory
submissions
related
ongoing
new
clinical
trials
product
candidates
timing
announcement
clinical
data
product
candidates
likelihood
data
positive
support
clinical
development
regulatory
approval
product
candidates
likelihood
approval
product
candidates
applicable
regulatory
authorities
orchard
financial
condition
cash
runway
statements
neither
promises
guarantees
subject
variety
risks
uncertainties
many
beyond
orchard
control
could
cause
actual
results
differ
materially
contemplated
statements
particular
risks
uncertainties
include
without
limitation
risk
one
orchard
product
candidates
including
product
candidates
referred
release
approved
successfully
developed
commercialized
risk
cessation
delay
orchard
ongoing
planned
clinical
trials
risk
orchard
may
successfully
recruit
enroll
sufficient
number
patients
clinical
trials
risk
prior
results
signals
safety
activity
durability
effect
observed
preclinical
studies
clinical
trials
replicated
continue
ongoing
future
studies
trials
involving
orchard
product
candidates
including
libmeldy
insufficient
support
regulatory
submissions
marketing
approval
us
eu
adverse
safety
findings
may
discovered
delay
orchard
regulatory
submissions
failure
obtain
marketing
approval
applicable
regulatory
authorities
orchard
product
candidates
including
risk
marketing
authorization
application
submitted
libmeldy
may
approved
european
commission
expected
receipt
restricted
marketing
approvals
inability
risk
delays
orchard
ability
commercialize
product
candidates
including
libmeldy
approved
including
risk
orchard
may
secure
adequate
pricing
reimbursement
support
continued
development
commercialization
libmeldy
risk
market
opportunity
product
candidates
including
libmeldy
may
lower
estimated
severity
impact
pandemic
orchard
business
including
clinical
development
supply
chain
commercial
programs
given
uncertainties
reader
advised
place
undue
reliance
statements
risks
uncertainties
faced
orchard
include
identified
heading
risk
factors
orchard
quarterly
report
form
quarter
ended
september
filed
securities
exchange
commission
sec
well
subsequent
filings
reports
filed
sec
statements
contained
press
release
reflect
orchard
views
date
hereof
orchard
assume
specifically
disclaims
obligation
publicly
update
revise
statements
whether
result
new
information
future
events
otherwise
except
may
required
law
condensed
consolidated
statements
operations
thousands
except
share
per
share
amounts
unaudited
three
months
ended
september
product
sales
net
costs
operating
expenses
cost
product
sales
research
development
selling
general
administrative
total
costs
operating
expenses
loss
operations
income
expense
interest
income
interest
expense
income
expense
net
total
income
expense
net
net
loss
income
tax
income
tax
expense
benefit
net
loss
attributable
ordinary
shareholders
net
loss
per
share
attributable
ordinary
shareholders
basic
diluted
weighted
average
number
ordinary
shares
outstanding
basic
diluted
condensed
consolidated
balance
sheet
data
thousands
unaudited
september
december
assets
current
assets
cash
cash
equivalents
marketable
securities
trade
receivables
prepaid
expenses
current
assets
research
development
tax
credit
receivable
current
total
current
assets
assets
operating
lease
property
equipment
net
research
development
tax
credit
receivable
assets
total
assets
liabilities
shareholders
equity
current
liabilities
accounts
payable
accrued
expenses
current
liabilities
operating
lease
liabilities
notes
payable
current
total
current
liabilities
notes
payable
operating
lease
liabilities
net
current
portion
liabilities
total
liabilities
shareholders
equity
total
liabilities
shareholders
equity
contacts
investors
renee
leck
director
investor
relations
media
christine
harrison
vp
corporate
affairs
media
